We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Fx41.8
FOXO4-DRI Research
Mostly mechanism / observational
6 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most FOXO4-DRI studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2017–2026 with a typical study size of 18 participants.
Based on 6 studies · 18 total participants
Confidence
Low confidence
By outcome
Senescence & aging (preclinical)Selective senescent-cell clearance and restored tissue function in preclinical models; no human data, with the inherent risks of senolysis. · Not established (no human data)
Mostly mechanism / observational6 studies
Tumor microenvironment
Mostly mechanism / observational4 studies
Active research area
4 studies in the last 5 years
20172026
1Reviewn=18 · very small study2026
In plain English: Clinical translation of FOXO4-p53 disruption requires isoform- and tissue-specific validation, pharmacokinetic and delivery studies, long-term toxicology, and explicit assessment of p53-dependent tumor surveillance.
Mateescu DM, Gavrilescu DM, Marinescu AR, Rosca O, Lazureanu VE, Ilie AC, Muresan CO, Enache A. · Antioxidants (Basel, Switzerland) (2026)
By contrast, direct FOXO4 regulation of commonly cited antioxidant targets, including SOD2, catalase, sestrins, and GADD45, remains insufficiently demonstrated and is inferred mainly from FOXO3 or broader FOXO-family studies.
Clinical translation of FOXO4-p53 disruption requires isoform- and tissue-specific validation, pharmacokinetic and delivery studies, long-term toxicology, and explicit assessment of p53-dependent tumor surveillance.